Febrile Seizure Risk Following Monovalent COVID-19 mRNA Vaccination in US Children Aged 2-5 Years

3 4

5

6

7

Steven A Anderson, PhD, MPP,¹ Elizabeth R Smith, BS,² Zhiruo Wan, MS², Kandace L Amend, PhD, MPH,³ Alex Secora, PhD⁴, Djeneba Audrey Djibo, PhD, MSBME,⁵ Kamran Kazemi, BS,² Jennifer Song, MA, MURP³, Lauren E Parlett, PhD⁶, John D Seeger, DrPH, PharmD³, Nandini Selvam, PhD, MPH⁴, Cheryl N McMahill-Walraven, PhD, MSW,⁵ Mao Hu, BS,² Yoganand

- 8 Chillarige, MPA², Richard A Forshee, PhD¹
- 9
- Affiliations: ¹US Food and Drug Administration, Silver Spring, MD, USA; ²Acumen LLC,
 Burlingame, CA, USA; ³Optum Epidemiology, Boston, MA, USA; ⁴IQVIA, Falls Church, VA,
- Burlingame, CA, USA; ³ Optum Epidemiology, Boston, MA, USA; ⁴ IQVIA, Falls Church, VA
 USA; ⁵ CVS Health, Blue Bell, PA, USA; ⁶ Carelon Research, Inc., Wilmington, DE, USA
 13
- 13 14
- Address correspondence to: Richard A. Forshee, PhD, Deputy Director, Office of Biostatistics
- and Pharmacovigilance, Center for Biologics Evaluation and Research, U.S. Food & Drug
- 17 Administration, 10903 New Hampshire Ave., Silver Spring, MD, 20993,
- 18 <u>richard.forshee@fda.hhs.gov</u>, (240) 402-8631
 19
- 20 Short title: Febrile Seizure Following COVID-19 mRNA Vaccination
- 21
- 22 **Conflict of Interest Disclosures:** Both Drs Djibo and McMahill-Walraven are CVS Health
- 23 employees.
- 24 **Data Sharing Statement:** The study protocol was posted previously. Data analyses and related
- 25 documents can be made available where needed, by contacting the corresponding author. De-
- 26 identified participant data will not be shared without approval from the data partners.
- 27
- **Funding/Support:** The US Food and Drug Administration provided funding for this study and
- contributed as follows: led the design of the study, interpretation of the results, writing of the
- 30 manuscript, decision to submit, and made contributions to the coordination of data collection and
- 31 analysis of the data.
- 32

33 Abbreviations:

- 34 BEST Biologics Effectiveness and Safety
- 35 CBER Center for Biologics Evaluation and Research
- 36 CI Confidence Interval
- 37 CPT Current Procedural Terminology
- 38 CVX IIS code indicating vaccination
- 39 DTaP Diphtheria, Tetanus, Pertussis
- 40 EUA Emergency Use Authorization
- 41 FDA Food and Drug Administration
- 42 HCPCS Healthcare Common Procedure Coding System
- 43 ICD-10-CM International Classification of Diseases, Tenth Revision, Clinical Modification
- 44 IIS Immunization Information System

- 45 IRR Incidence Rate Ratio
- 46 MMR/MMRV Measles, Mumps, Rubella/Measles, Mumps, Rubella, Varicella
- 47 mRNA Messenger ribonucleic acid
- 48 NDC National Drug Codes
- 49 NRS Near Real-Time Surveillance
- 50 PCV13 Pneumococcal Conjugate Vaccine
- 51 PPV Positive Predictive Value
- 52 RD Risk Difference
- 53 SAE Systemic Adverse Event
- 54 SCCS Self-Controlled Case Series
- 55 U.S. United States
- 56 VAERS Vaccine Adverse Event Reporting System
- 57 58

59 Article Summary

- 60 In this self-controlled case series study, researchers evaluated whether there is an elevated risk of
- 61 febrile seizure immediately following monovalent COVID-19 mRNA vaccination.
- 62 63

64 What's Known on This Subject

- 65 The United States Food and Drug Administration previously noted a potential safety concern for
- seizure in children aged 2-5 years receiving the ancestral monovalent COVID-19 mRNA
- 67 vaccines.
- 68

69 What This Study Adds

- 70 In this self-controlled case series that included participants aged 2-5 years from three commercial
- 71 insurance databases, the incidence rate ratio of febrile seizures was significantly elevated in the
- 72 0-1 days following mRNA-1273 administration. Absolute risk was small.

74 Contributors Statement

- 75 Steven A Anderson and Richard A Forshee conceptualized and designed the study, interpreted
- data and analysis, drafted the manuscript, critically reviewed and revised the manuscript, and
- 77 provided supervision of the analysis.
- Elizabeth R Smith conceptualized and designed the study, interpreted data and analysis, draftedthe manuscript, and critically reviewed and revised the manuscript.
- 80 Zhiruo Wan, Kamran Kazemi, and Mao Hu conceptualized and designed the study, designed
- data collection instruments, carried out the data analysis, and critically reviewed and revised themanuscript.
- Yoganand Chillarige conceptualized and designed the study, critically reviewed and revised the
 manuscript, and provided supervision of the analysis.
- 85 Kandace L Amend, Alex Secora, Djeneba Audrey Djibo, Jennifer Song, Lauren E Bartlett, John
- 86 D Seeger, Nandini Selvam, and Cheryl N McMahill-Walraven carried out data analysis and
- 87 critically reviewed and revised the manuscript.
- 88 All authors approved the final manuscript as submitted and agree to be accountable for all
- 89 aspects of the work.

90			
91			
92			
93			
94			
95			
96			
97			
98			
99			
100			
101			
102			
103			
104			
105			
106			

107

108

109 ABSTRACT (Word Count: 244)

110 **Objective**

- 111 To evaluate febrile seizure risk following monovalent COVID-19 mRNA vaccination among
- 112 children aged 2-5 years.

113 Methods

- 114 The primary analysis evaluated children who had a febrile seizure outcome in the 0-1 days
- following COVID-19 vaccination. A self-controlled case series analysis was performed in three
- 116 commercial insurance databases to compare the risk of seizure in the risk interval (0-1 days) to a
- 117 control interval (8-63 days).
- The exposure of interest was receipt of dose 1 and/or dose 2 of monovalent COVID-19 mRNAvaccinations.
- 120 The primary outcome was febrile seizure (0-1 day risk interval).
- 121 A conditional Poisson regression model was used to compare outcome rates in risk and control
- 122 intervals and estimate incidence rate ratios (IRR) and 95% confidence intervals (CIs). Meta-
- analyses were used to pool results across databases.

124 **Results**

- 125 The primary meta-analysis found a statistically significant increased incidence of febrile seizure,
- in the 0-1 days following mRNA-1273 vaccination compared to the control interval (IRR: 2.52,
- 127 95% CI: 1.35 to 4.69, risk difference (RD)/100,000 doses = 3.22 (95% CI -0.31 to 6.75)). For the
- 128 BNT162b2 vaccination, the IRR was elevated but not statistically significant (IRR: 1.41, 95%CI:
- 129 0.48 to 4.11, RD/100,000 doses = -0.25 (95% CI -2.75 to 2.24).

130 Conclusions

- 131 Among children aged 2-5 years, the analysis showed a small elevated incidence rate ratio of
- 132 febrile seizures in the 0-1 days following the mRNA-1273 vaccination. Based on the current
- body of scientific evidence, the safety profile of the monovalent mRNA vaccines remains
- 134 favorable for use in young children.
- 135
- 136

137 INTRODUCTION (Word Count: 586)

On June 17, 2022 the United States (U.S.) Food and Drug Administration (FDA) granted 138 139 emergency use authorization (EUA) for the monovalent COVID-19 mRNA vaccines developed 140 by Pfizer-BioNTech (BNT162b2) for use in individuals aged 6 months through 4 years, and Moderna (mRNA-1273) for use in individuals aged 6 months through 17 years.¹ The BNT162b2 141 142 vaccine was authorized as a three-dose primary series, and the mRNA-1273 vaccine was authorized as a two-dose primary series in young children. As of April 18, 2023 these initial 143 formulations of the mRNA vaccines are no longer available for use and have been replaced by 144 updated formulations based on currently circulating variants.² 145 Fever was one of the commonly observed systemic adverse events (SAEs) in children in the 146 clinical trials of both mRNA vaccines, and in some instances, may result in febrile seizures. In 147 clinical trials of mRNA-1273 vaccinations among individuals aged 24-36 months, ³ fever 148 (≥38.0°C) was observed in 11.3% and 18.9% of participants following dose 1 and 2, 149 respectively. Grade 3 fever (39.6°C-40.0°C) was observed in 0.3% and 1.2% of participants 150 151 following dose 1 and 2, respectively, and grade 4 fever (>40.0 $^{\circ}$ C) was observed in 0.3% and 0.3% of participants following dose 1 and 2. Fever was the most common grade 3/4 SAE 152 observed in individuals aged 37 months – 5 years. Fever (\geq 38.0°C) was observed in 7.7% and 153 154 16.0% of participants aged 37 months – 5 years following dose 1 and 2, respectively. Grade 3 fever (39.0°C-40.0°C) was observed in 1.1% and 2.9% of participants following dose 1 and 2, 155 and grade 4 fever (>40.0 $^{\circ}$ C) was observed in 0% and 0.2% of participants following dose 1 and 156 2. 157

For BNT162b2, the most common severe systemic reaction among individuals aged 2-4 years was fever.⁴ Fever (\geq 38.0°C) was observed in 5.2%, 4.9% and 5.1% of participants following

160	dose 1, 2, and 3 respectively. Fever (>38.9°C to 40.0°C) was observed in 0.7%, 1.1%, and 0.7%
161	of participants following dose 1, 2, and 3 respectively, and fever (>40.0°C) was observed in
162	0.1%, 0.1%, and 0% of participants following dose 1, 2, and 3.
163	In a prior safety monitoring study, the FDA Center for Biologics Evaluation and Research
164	(CBER) conducted near real-time surveillance (NRS) of the authorized COVID-19 vaccines in
165	the pediatric population. ^{5,6} NRS allows for the rapid identification of statistical signals for
166	potentially elevated risk of evaluated outcomes following vaccination. Of the 19 outcomes
167	evaluated for increased risk following exposure to the monovalent COVID-19 vaccines, the NRS
168	detected a statistical signal for seizures/convulsions across the different doses (dose 1 and/or
169	dose 2) following exposure to BNT162b2 in individuals aged 2-4 years and mRNA-1273 in
170	individuals aged 2-5 years. Further evaluation of the potential signal was necessary as NRS was
171	designed to be sensitive but not specific for screening and detection purposes.
172	The NRS used a broad outcome definition for seizures/convulsions and evaluated a 0-7 day risk
173	interval. However, further examination of the data used in the NRS study indicated that most of
174	the identified seizures/convulsions cases were febrile seizures. Accordingly, this current study
175	uses the febrile case definition for children under the age of 5 years and a risk interval of 0-1
176	days, as used in prior FDA studies, to ensure that febrile cases are more likely to be associated
177	with vaccination rather than other causes. ⁷ This manuscript summarizes results of a self-
178	controlled case series (SCCS) study conducted in 3 commercial insurance databases in the
179	pediatric population aged 2-5 years. The primary objective was to determine the risk of febrile
180	seizure in the 0-1 days following vaccination.

METHODS (Word Count: 755) 181

182 Data Sources

- This study used commercial health claims data from the Carelon Research, CVS Health, and
 Optum databases to capture COVID-19 vaccination data and medical claims data relevant to the
 outcomes of interest. COVID-19 vaccination data from participating Immunization Information
 System (IIS) jurisdictions were used to supplement claims data to improve capture of COVID-19
 vaccinations (eTable 1). ⁸
- 188 Study Population, Study Period, and Study Design

189 The study population consisted of enrollees aged 2-4 years who received a BNT162b2 COVID-

190 19 vaccination and enrollees aged 2-5 years who received a mRNA-1273 COVID-19

vaccination. To be included in the study population, individuals were required to be continuously

192 enrolled in the health plan at least 42 days prior to receiving the vaccine dose of interest.

193 Individuals were excluded if they had COVID-19 vaccination patterns that did not conform to

194 expectations for the analysis of interest, such as subsequent doses occurring fewer than 3 days

apart or receipt of more doses than approved. The start of the study period was June 17, 2022,

the EUA for COVID-19 vaccinations in these age groups. The study end date was database

197 specific (eTable 1).

198 We used a SCCS study design to compare the incidence of seizure outcomes following

199 monovalent COVID-19 pediatric vaccine administration within pre-specified risk intervals

200 (primary outcome: febrile seizures, 0-1 days; secondary outcomes: febrile seizures, 0-7 days and

seizures/convulsions, 0-7 days) to a control interval (day 8 through the end of the 63 day

observation period). In the primary outcome analysis, we included a washout period (days 2-7)

203 prior to the control interval; for secondary outcomes, this period was included in the risk interval.

204 Exposures and Outcomes

The primary exposure of interest was the receipt of dose 1 and/or dose 2 of the monovalent 205 206 COVID-19 BNT162b2 (individuals aged 2-4 years) or mRNA-1273 (individuals aged 2-5 years) 207 pediatric vaccines. Vaccinations were identified in administrative claims data through vaccinespecific codes including Current Procedural Terminology (CPT)/Healthcare Common Procedure 208 209 Coding System (HCPCS) codes and National Drug Codes (NDCs) in the professional, outpatient, inpatient, or pharmacy care settings, as well as CVX (vaccine administered codes) in IIS data 210 (eTable 2). 211 The primary outcome of interest was febrile seizures (0-1 day risk window). Secondary 212 outcomes included febrile seizures (0-7 day risk window) and seizures/convulsions (0-7 day risk 213 214 window). Seizure outcomes were identified with International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes in any diagnosis position in the inpatient 215 216 and emergency department settings. Febrile seizures were identified using ICD-10-CM codes R56.00 and R56.01; seizures/convulsions were identified using ICD-10-CM codes R56.00, 217 R56.01, and R56.9. Incident seizure outcomes were defined as the first recorded seizure event for 218 219 an individual during the observation period following the exposure, with no previously identified outcomes in the 42-day clean interval prior to outcome. 220

221 Statistical Analysis

We characterized all eligible vaccinees as well the subset of vaccinees with outcomes, including stratification by age, sex, U.S. region, and concomitant vaccination status. We used a conditional Poisson regression model to compare the febrile seizure rates in risk and control intervals and estimate the incidence rate ratio (IRR). From the conditional Poisson regression model, we

derived the risk difference (RD) per 100,000 vaccinations and per 100,000 person-years.⁹ We 226 performed meta-analyses to pool results from all three databases, allowing for higher precision 227 and statistical power. Meta-analyses were prespecified as primary and individual database results 228 were specified as secondary. We conducted random-effects meta-analysis to account for 229 between-study heterogeneity across multiple data sources and fixed-effect meta-analysis to 230 231 address concerns that the random-effects method may not perform well when the number of studies is small. Random-effects meta-analyses are reported in text. We used Cochran's Q 232 statistic and Higgins & Thompson's I² statistic to assess between-study heterogeneity.¹⁰ 233 234 We conducted a sensitivity analysis restricting to enrollees without concomitant MMR/MMRV (Measles, Mumps, Rubella/Measles, Mumps, Rubella, Varicella), DTaP (Diphtheria, Tetanus, 235 236 Pertussis), PCV13 (Pneumococcal Conjugate Vaccine), or influenza vaccination on the same day as COVID-19 vaccination. We also adjusted for potential time-varying confounding due to the 237 238 length of the observation period by adjusting for baseline febrile seizure risk estimated from within-study background rates. We conducted a sensitivity analysis implementing the Farrington 239 240 adjustment for event-dependent exposure.¹¹ Finally, we conducted a sensitivity analysis adjusting for the PPV of our primary outcome using the Schenker and Rubin method and the PPV derived 241 by the Sentinel initiative (PPV 91%; 95% CI 85-95%).^{11,12} Medical record review of the cases 242 identified in the present study is ongoing. 243

All analyses were conducted using R (version 4.1.2, R Foundation for Statistical Computing) and
SAS v. 9.4 (SAS Institute Inc., Cary, NC, United States).

246 **RESULTS (Word Count: 638)**

247 **Primary Outcome**

248 **Descriptive Analyses**

249	There were 288,754 BNT162b2 and 192,540 mRNA-1273 vaccinations observed among
250	163,733 and 110,126 enrollees, respectively. In the primary analysis, 88 cases of febrile seizures
251	were observed following vaccination with BNT162b2, of which 7 cases were observed during
252	the risk interval (days 0-1) and 81 were observed during the control interval (days 8-63) (Table
253	1). There were 67 cases of febrile seizures observed following vaccination with mRNA-1273, of
254	which 10 cases were observed during the risk interval (days 0-1) and 57 during the control
255	interval (days 8-63).

as well as the population who experienced an outcome in the primary analysis. Among all

Table 1 provides a summary of the baseline characteristics of the eligible vaccinated population

eligible vaccinees, sex was evenly distributed and age was generally evenly distributed.

However, the population experiencing outcomes skewed younger than the 'all eligible vaccinees'

population, with a greater proportion of cases observed in those aged 2 years compared to all

other age groups.

256

262 Inferential Analyses

263 Meta-analyzed IRRs for primary and sensitivity analyses are presented in Figure 1 and Table 2.

264 The primary meta-analysis found more than twice the incidence of the primary outcome febrile

seizure 0-1 days following the mRNA-1273 vaccine compared to control interval (IRR: 2.52,

266 95% CI: 1.35 to 4.69) with low between-database heterogeneity ($I^2=0\%$, 95% uncertainty

interval 0-78%; Cochran's Q test p-value = 0.62). For the BNT162b2 vaccination, the IRR was

- elevated but not statistically significant (IRR: 1.41, 95%CI: 0.48 to 4.11) with moderate
- between-database heterogeneity ($I^2=51\%$, 95% uncertainty interval 0-86%; Cochran's Q test p-

270	value = 0.13). We estimated a RD of 3.22 (95%CI -0.31 to 6.75) febrile seizure events per
271	100,000 mRNA-1273 vaccinations, and -0.25 (95%CI -2.75 to 2.24) febrile seizure events per
272	100,000 BNT162b2 vaccinations (Table 3).
273	Sensitivity analysis results were consistent in direction and magnitude with the primary analysis
274	(Figure 1). Farrington-adjusted analyses yielded an IRR of 2.43 (95% CI: 1.35 to 4.69) following
275	mRNA-1273 and 1.26 (95%CI: 0.38 to 4.15) following BNT162b2. Analysis on the subset of the
276	population without concomitant vaccinations yielded an IRR of 2.54 (95% CI: 1.19 to 5.42)
277	following mRNA-1273 and 1.64 (95%CI: 0.61 to 4.42) following BNT162b2. Analyses
278	adjusting for seasonality of seizures resulted in an IRR of 2.51 (95% CI: 1.27 to 4.96) following
279	mRNA-1273 and 1.31 (95%CI: 0.42 to 4.01) following BNT162b2. Finally, PPV-adjusted
280	analyses showed an IRR 2.53 (95% CI: 1.17 to 5.47) following mRNA-1273 and 1.38 (95% CI:
281	0.48 to 4.02) following BNT162b2.
282	IRRs from analyses in individual databases are displayed in eFigure 1. IRRs following
283	mRNA1273 were consistently elevated across databases, though only the results in the CVS
284	Health database were significant (Optum IRR=2.19, 95% CI: 0.49 to 9.85; Carelon IRR=1.68,
285	95% CI: 0.5 to 5.61; CVS IRR=3.59, 95% CI: 1.33 to 9.67). IRRs showed more variation
286	between databases following BNT16b2 vaccination, with significant elevated incidence rate
287	ratios observed only in the Optum database (Optum IRR=3.07, 95% CI: 1.04 to 9.10; Carelon
288	IRR=0.43, 95% CI: 0.06 to 3.17; CVS IRR=0.96, 95% CI: 0.23 to 4.03). Sensitivity analysis
289	results from individual databases were largely consistent with the primary analysis results from
290	the databases.

291 Secondary Outcomes

In the secondary outcomes using a longer risk interval (0-7 days), there were 103 cases of febrile seizures and 135 cases of seizures/convulsions observed following vaccination with BNT162b2, of which 22 cases of febrile seizures and 32 cases of seizures/convulsions were observed during the risk interval. There were 78 cases of febrile seizures and 106 cases of seizures/convulsions observed following vaccination with mRNA-1273, of which 21 cases of febrile seizures and 28 cases of seizures/convulsions were observed during the risk interval.

No statistically significant results were observed in the meta-analysis nor in individual databases
for the secondary outcomes (eFigures 2-3). Additionally, no statistically significant results were

300 observed for the secondary outcome populations in any of the analyses with adjustments.

301 **DISCUSSION** (Word Count: 979)

302 In our study of large cohorts aged 2-5 years in three U.S. commercial health insurance databases,

303 our primary meta-analysis identified a statistically significant increased incidence of febrile

seizures among ages 2-4 years in the 0-1 days following mRNA-1273 vaccination. No

significantly increased incidence was identified following BNT162b2 vaccination among ages 2-

5 years. Database specific results showed increased incidence of febrile seizure immediately

following BNT162b2 vaccination in the Optum database and for the mRNA-1273 vaccine in the

308 CVS Health database. No significant increased incidence was identified for secondary outcomes

including febrile seizures in the 0-7 days following vaccination and seizures/convulsions in the

310 0-7 day risk window.

311 Though our primary meta-analysis showed a relative risk near 2.5 for febrile seizures

312 immediately following mRNA-1273 vaccination, we estimated the risk difference of febrile

seizures following vaccination to be small. In the 0-1 day risk interval following over 190,000

314	eligible mRNA-1273 vaccinations only 10 febrile seizure cases were observed. Our analysis
315	found a risk difference of approximately 3 additional cases of febrile seizures per 100,000
316	mRNA-1273 vaccinations, though the range from the confidence interval for the estimate
317	included the potential for fewer than zero febrile seizure events per 100,000 vaccinations. The
318	uncertainty in our estimates reflected the rarity of the event. We did not find a statistically
319	significant estimate following BNT162b2 vaccination. Furthermore, there was a lack of
320	consistency in directionality of the incidence rate ratio and attributable risk estimates following
321	BNT1262. This uncertainty is likely due to variation from small case counts and a small number
322	of databases contributing to the meta-analysis.
323	Our meta-analysis results showed a significantly increased incidence following mRNA-1273 but
324	not following BNT162b2 vaccination. The difference in formulation of the two vaccinations may
325	yield a different immune reaction. The mRNA-1273 vaccination contains 25 μ g of antigen per
326	0.25mL dose, while the BNT162b2 vaccination contains 3 μ g of antigen per 0.3mL dose.
327	Other studies from clinical trials, active surveillance systems, and passive surveillance systems
328	found febrile seizures to be rare and did not report any increased risk for febrile seizures
329	following COVID-19 vaccination in children under 5 years of age. Initial vaccine safety data
330	indicate that among young children, seizures/convulsions following COVID-19 mRNA vaccines
331	are rare: A clinical trial of 3,013 vaccine recipients in children aged 6 months to 4 years reported
332	5 febrile convulsions cases and only one of those (in a 6-month-old participant) was considered
333	possibly related to the BNT162b2 vaccination or may also have been caused by a concurrent
334	viral infection. ¹³ In an analysis of the passive surveillance Vaccine Adverse Event Reporting
335	System (VAERS) data, only 8 seizures were identified following approximately one million
336	COVID-19 mRNA vaccinations through August 2022 in the age group 6 months to 5 years. Six

of the 8 seizures were afebrile on medical evaluation.¹⁴ In CBER's NRS of the bivalent

formulations of the mRNA vaccines authorized in December 2022 for the youngest age groups,

no seizures/convulsions outcomes were identified in vaccinees aged 2-5 among 611 person-years

340 of follow up.

341 It is important to note that febrile seizures occur at rate of up to 5% in young children.¹⁵ The risk

difference we found of 3 additional cases of febrile seizures per 100,000 mRNA-1273

343 vaccinations is not large compared to some other vaccines and combinations of vaccines which

may carry a small risk of at most 30 febrile seizures in 100,000 children vaccinated.

345 Our study has several strengths. First, our study included a large, geographically diverse

population from three US commercial health insurance databases. Our use of a self-controlled

347 study design inherently adjusted for time-invariant confounders such as health conditions,

348 socioeconomic status, and demographic characteristics that may introduce bias in other study

designs using between-individual comparisons. We adjusted for time-varying confounding such
as seasonality in our sensitivity analyses. Our study sampled vaccinated cases from health plan
and public health authority data and not from individual-level reports of vaccination status and
therefore was not subject to bias due to underreporting of vaccination status. Our study used IIS

data to supplement claims-based vaccination information thus increasing sample size of SCCS

354 study for these rare outcomes. Finally, our outcome definition was shown to have a high PPV;¹⁶

therefore, our study was able to minimize potential outcome misclassification bias.

Our study also has some limitations. First, the rarity of the event led to substantial uncertainty in estimates, and our study was not powered to identify very small increases in risks. The small number of outcomes further prevented us from performing dose-specific analyses or further subgroup analyses. We may have omitted some beneficiaries with outcomes due to delayed

reporting; however, we selected study end dates to ensure 85% data completeness. Furthermore, 360 we conducted PPV adjustment using the Sentinel Initiative's PPV estimates as medical record 361 review for this study is still underway for our population. Sentinel Initiative's PPV estimates 362 may not be generalizable to our population as they were based on ICD-9 codes. Because of the 363 low number of databases in the meta-analysis, the statistics for measuring heterogeneity between 364 365 studies could be biased. Due to low observed counts and different formulation, this study focused 366 on monovalent mRNA vaccines and did not include bivalent formulations. Finally, though we 367 did adjust for seasonality, there may be additional bias from unmeasured time-varying covariates 368 such as circulating respiratory viruses such as SARS-CoV-2 and influenza.

369 Conclusions

370 Our study found an approximately 2.5 times increased incidence of febrile seizures among those

aged 2-4 years in the 0-1 days following monovalent mRNA-1273 vaccination. However,

absolute risk was low. Based on the current body of scientific evidence, the safety profile of the

373 monovalent mRNA vaccines remains favorable for use in young children. Safety monitoring

374 continues as new COVID-19 vaccines become available for children. This study was conducted

under the FDA Biologics Effectiveness and Safety (BEST) Initiative, which plays a major role in

the larger US federal government vaccine safety monitoring efforts and further supports

377 regulatory decision-making regarding COVID-19 vaccines.

378

379

380 381

- 383
- 384
- 385

Acknowledgements: Bowen Chen, Vincent Varvaro, Xi Li of Acumen, LLC; Shiva Vojjala, 386 387 Ramya Avula, Shiva Chaudhary, Shanthi P Sagare, Ramin Riahi, Brian Greenwald, Mia Si, Dianna Hayden, and Grace Stockbower of Carelon Research; Michael Goodman, Ken Revett, 388 389 Ruth Weed, and Nerissa Williams of IQVIA; Lauren Peetluk, PhD, MPH, Elizabeth J. Bell, PhD, MPH, Wafa Tarazi, PhD, MHPA, Alexandra Stone, PhD, MS of Optum; and Anne Marie Kline 390 MS, CHES, Nancy B. Shaik, BS, Ana M Martinez-Baquero, MA, Vaibhav Sharma, MS, Smita 391 Bhatia, MCA, Yi Liu, MDA, MS, Xun Zhang, MMS, Eugenio Abente, PhD, Jonathan P 392 393 Deshazo, PhD, MPH, Aparna Srikanti, MSc, Ralph Webber, BS, Charlalynn Harris, PhD, MPH, Wuan M Head, BA, Harpreet Kaur Dhillon, MCA, Carla Brannan, BA, Jack Dimpel, and James 394 395 Dunlap of CVS Health for their assistance with data validation, analysis, and project 396 coordination. 397 398 399 400 401

403 **References**

404	1.	U.S. Food & Drug Administration, Coronavirus (COVID-19) Update: FDA Authorizes
405		Moderna and Pfizer-BioNTech COVID-19 Vaccines for Children Down to 6 Months of
406		Age. 2022: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-
407		19-update-fda-authorizes-moderna-and-pfizer-biontech-covid-19-vaccines-children.
408		2023
409	2	Centers for Disease Control and Prevention. Stay Up to Date with COVID-19 Vaccines
410	2.	2023. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-un-to-date.html 2023
411	3	U.S. Food & Drug Administration, Vaccines and Related Biological Products Advisory
412	2.	Committee Meeting: FDA Review of Effectiveness and Safety of Moderna COVID-19
413		Vaccine in Children 6 Months through 5 Years of Age. Emergency Use Authorization
414		Amendment 2022: https://www.fda.gov/media/159254/download
415	4	U.S. Food & Drug Administration, Vaccines and Related Biological Products Advisory
416	1.	Committee Meeting: FDA Review of Effectiveness and Safety of Pfizer-BioNTech
417		COVID-19 Vaccine in Children 6 Months through 4 Years of Age Emergency Use
418		Authorization Amendment 2022: https://www.fda.gov/media/159255/download
410 //10	5	U.S. Food & Drug Administration COVID-19 Vaccine Safety Surveillance 2021:
420	5.	https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/covid-19-
420		vaccine-safety-surveillance 2023
421	6	Hu M Shoaibi A Feng Y et al Safety of Monovalent BNT162b2 (Pfizer-BioNTech)
422	0.	mRNA-1273 (Moderna) and NVX-CoV2373 (Novayax) COVID-19 Vaccines in US
423		Children A ged 6 months to 17 years 2023:2023 2010 2013 23296903
425	7	Kawai AT Martin DB Kulldorff M et al Assessment of Febrile Seizures After Trivalent
425	7.	Inluenza Vaccines During the 2010-2011 Influenza Season in the Post-Licensure Ranid
420		Immunization Safety Monitoring Program Mini-Sentinel: U.S. Food & Drug
427 128		Administration: 2014
420	8	U.S. Food & Drug Administration FDA Evaluation of a Preliminary Seizure Safety
420	0.	Signal from Rapid Surveillance of Children Ages $2 - 4/5$ yrs following COVID-19
430		mRNA Vaccination 2023: https://bestinitiative.org/wn-
431		content/unloads/2023/07/BEST Prelim Seizure Safety Signal Ages-2-5 2023 ndf
432		2023
433	9	Wilson K Hawken S Drug safety studies and measures of effect using the self-controlled
435).	case series design <i>Pharmacoenidemiology and Drug Safety</i> 2012:22(1):108-110
435	10	Higgins IPT Thompson SG Quantifying heterogeneity in a meta-analysis
430	10.	2002·21(11)·1539-1558
437	11	Earrington CP Whitaker HI Hocine MN Case series analysis for censored perturbed or
430	11.	curtailed post-event exposures <i>Biostatistics</i> 2009.10(1):3-16
435	12	Rubin DB Schenker N Multiple Imputation for Interval Estimation From Simple
441	12.	Random Samples With Ignorable Nonresponse. <i>Journal of the American Statistical</i>
442		Association 1986:81(394):366-374
443	13	U.S. Food & Drug Administration, Vaccines and Related Biological Products Advisory
444	10.	Committee Meeting June 15, 2022. FDA Briefing Document: FUA amendment request
445		for Pfizer-BioNTech COVID-19 Vaccine for use in children 6 months through 4 years of
446		age In:2022
		"Do. m.zozz.

- Hause AM, Marquez P, Zhang B, et al. COVID-19 mRNA Vaccine Safety Among 14. 447 448 Children Aged 6 Months–5 Years — United States, June 18, 2022–August 21, 2022. Morbidity and Mortality Weekly Report (MMWR): Centers for Disease Control and 449 450 Prevention; September 2, 2022 2022. 15. Centers for Disease Control and Prevention. Febrile Seizures. 451 https://www.cdc.gov/vaccinesafety/concerns/febrile-452 seizures.html#:~:text=A%20CDC%20study%20of%20children,tetanus%2C%20acellular 453 454 %20pertussis%20(DTaP). Accessed February 6, 2024. Kawai AT, Martin D, Henrickson SE, et al. Validation of febrile seizures identified in the 16. 455 Sentinel Post-Licensure Rapid Immunization Safety Monitoring Program. Vaccine. 456 457 2019;37(30):4172-4176. 458 459 460 461 462 463 464 465
- 466

467 **Figures Legend**

- 468 Figure 1. Incidence Rate Ratios for Primary and Sensitivity Random-Effects Meta-Analyses,
- Febrile Seizures (0-1 Days) Outcome illustrates incidence rate ratios and 95% confidence
- 470 intervals across analyses for direct comparison.
- 471 Figure e1. Incidence Rate Ratios, Random Effects Meta-Analysis and Individual Database
- 472 Results, Primary Outcome: Febrile Seizure (0-1 Day Risk Interval) illustrates incidence rate
- 473 ratios and 95% confidence intervals across individual databases for all analyses of the primary
- 474 outcome.
- 475 eFigure 2. Incidence Rate Ratios, Random Effects Meta-Analysis and Individual Database
- 476 Results, Secondary Outcome: Febrile Seizure (0-7 Day Risk Interval) illustrates incidence rate
- ratios and 95% confidence intervals across individual databases for all analyses of the secondary
- 478 febrile seizure outcome.
- eFigure 3. Incidence Rate Ratios, Random Effects Meta-Analysis and Individual Database
- 480 Results, Secondary Outcome: Seizure (0-7 Day Risk Interval) illustrates incidence rate ratios and
- 481 95% confidence intervals across individual databases for all analyses of the secondary
- 482 seizure/convulsion outcome.
- 483
- 484
- 485
- 486
- 487
- 488
- 489
- 490
- 491
- 492
- 493
- 494
- 495
- 496
- 497
- 498
- 499

500 **Tables**

Table 1. Characteristics of Vaccinated Patients and Patients With Febrile Seizures Aged 2-4 Years 501 (BNT162b2) and 2-5 Years (mRNA-1273), Combined Across Databases 502

				BNT16	52b2							mRNA-:	1273			
					Out	come							Out	come		
Patient	Eligi	ible		Febril	e Seizı	ure (0-1	Days)		Eligi	ble		Febril	e Seizı	ıre (0-1	Days)	
Characteristic	Vacci	nees	Ris Cor Inte	sk & ntrol ervals	In I Inte	Risk erval	In Co Inte	ontrol erval	Vacci	nees	Ris Cor Inte	sk & ntrol ervals	In I Inte	Risk erval	In Co Into	ontrol erval
	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
Total	163,733	100.0%	88	100.0%	7	100.0%	81	100.0%	110,126	100.0%	67	100.0%	10	100.0%	57	100.0%
Age																
2 years	53,485	32.7%	52	59.1%	*	*	*	*	35,300	32.1%	42	62.7%	5	50.0%	37	64.9%
3 years	56,052	34.2%	19	21.6%	*	*	*	*	35,075	31.8%	17	25.4%	*	*	*	*
4 years	54,196	33.1%	17	19.3%	*	*	*	*	34,520	31.3%	*	*	*	*	*	*
5 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	5,231	4.8%	*	*	*	*	*	*
Sex																
Female	80,214	49.0%	32	36.4%	*	*	*	*	53,967	49.0%	26	38.8%	6	60.0%	20	35.1%
Male	83,496	51.0%	56	63.6%	*	*	*	*	56,147	51.0%	41	61.2%	*	*	*	*
Missing/Unknown	23	0.0%	0	0.0%	0	0.0%	0	0.0%	12	0.0%	*	*	*	*	*	*
HHS Region																
Region 1	11,642	7.1%	10	11.4%	*	*	*	*	9,562	8.7%	9	13.4%	*	*	*	*
Region 2	17,878	10.9%	12	13.6%	*	*	*	*	16,074	14.6%	7	10.4%	*	*	*	*
Region 3	19,330	11.8%	8	9.1%	0	0.0%	8	9.9%	13,824	12.6%	10	14.9%	*	*	*	*
Region 4	21,098	12.9%	11	12.5%	0	0.0%	11	13.6%	10,597	9.6%	5	7.5%	*	*	*	*
Region 5	30,668	18.7%	18	20.5%	*	*	*	*	15,023	13.6%	5	7.5%	*	*	*	*
Region 6	14,344	8.8%	*	*	*	*	*	*	7,734	7.0%	*	*	*	*	*	*
Region 7	7,500	4.6%	*	*	*	*	*	*	4,216	3.8%	*	*	*	*	*	*
Region 8	7,859	4.8%	5	5.7%	0	0.0%	5	6.2%	4,359	4.0%	*	*	*	*	*	*
Region 9	27,105	16.6%	16	18.2%	0	0.0%	16	19.8%	22,382	20.3%	19	28.4%	*	*	*	*
Region 10	6,131	3.7%	*	*	*	*	*	*	6,230	5.7%	*	*	*	*	*	*
Missing/Unknown	178	0.1%	0	0.0%	0	0.0%	0	0.0%	125	0.1%	0	0.0%	0	0.0%	0	0.0%
Urban/Rural																
Urban	159,169	97.2%	86	97.7%	6	85.7%	80	98.8%	107,306	97.4%	65	97.0%	10	100.0%	55	96.5%
Rural	4,376	2.7%	*	*	*	*	*	*	2,680	2.4%	*	*	*	*	*	*
Missing/Unknown	188	0.1%	*	*	*	*	*	*	140	0.1%	*	*	*	*	*	*

503

*Cells <5 or cells that can be used to back calculate cells <5 are masked to avoid identification

504 Data cutoffs for 85% data completeness: Carelon Research -02/04/2023, CVS Health -03/26/2023, Optum -05/20/2023

505

		Cou Cá	unt of ases	Count	of Days	Ran Me	dom Eff ta-Anal	ects ysis	Fixed	Effects Analysi	Meta- s	Between	-Study \	/ar. (τ²)	Cochra	an's Q		l ²	
Analysis	Brand					DD	959		DD	959	% CI	Fet	954	% CI	Fet	P-Value	Ect	059	4 CI
		Risk	Control	Risk	Control	nn	337		ΝN	33,		LSI.	33.	/8 CI	LSI.	r-value	231.	33/	
Primary Analysis		7	81	296	4,318	1.41	0.48	4.11	1.85	0.94	3.62	0.43	0.00	36.07	4.07	0.13	0.51	0.00	0.86
Farrington-Adjusted		7	81	296	4,318	1.26	0.38	4.15	1.51	0.67	3.42	0.54	0.00	45.33	3.91	0.14	0.49	0.00	0.85
Non-Concomitant Vaccines	BNT- 162b2	7	65	252	3,547	1.64	0.61	4.42	1.81	0.81	4.03	0.23	0.00	31.36	2.88	0.24	0.31	0.00	0.93
Seasonality Adjusted		7	81	296	4,318	1.31	0.42	4.01	1.54	0.69	3.41	0.44	0.00	39.27	3.71	0.16	0.46	0.00	0.84
PPV-Adjusted		6	74	269	3,929	1.38	0.48	4.02	1.52	0.63	3.65	0.26	0.00	34.13	2.87	0.24	0.30	0.00	0.93
Primary Analysis		10	57	234	3,319	2.52	1.35	4.69	2.52	1.35	4.69	0.00	0.00	5.43	0.95	0.62	0.00	0.00	0.78
Farrington-Adjusted		10	57	234	3,319	2.43	1.20	4.90	2.43	1.20	4.90	0.00	0.00	3.23	0.51	0.77	0.00	0.00	0.59
Non-Concomitant Vaccines	mRNA- 1273	8	47	194	2,738	2.54	1.19	5.42	2.54	1.19	5.42	0.00	0.00	9.46	1.03	0.60	0.00	0.00	0.80
Seasonality Adjusted	12,5	10	57	234	3,319	2.51	1.27	4.96	2.51	1.27	4.96	0.00	0.00	4.79	0.83	0.66	0.00	0.00	0.90
PPV-Adjusted		9	52	213	3,017	2.53	1.17	5.47	2.53	1.17	5.47	0.00	0.00	5.86	0.80	0.67	0.00	0.00	0.90

507 Table 2. Incidence Rate Ratios for Primary and Sensitivity Meta-Analyses, Febrile Seizure (0-1 Days) Outcome

				Random-Effe			ffects Meta-	Analysis	Fixed Effects Meta-Analysis							
		Fligible	Eligible	RD P	er 100k D	oses	RD Per	100k Perso	n-Years	RD	Per 100k Do	ses	RD Per	100k Perso	n-Years	
Analysis	Brand	Vaccinations	Person- Years	AR	95%	S CI	AR	95	% CI	AR	95% CI		AR	95	% CI	
Primary Analysis		288,754	1,580.0	-0.25	-2.75	2.24	-46.01	-501.88	409.86	-0.66	-2.26	0.94	-120.57	-413.04	171.91	
Farrington-Adjusted		288,754	1,580.0	0.00	-2.55	2.55	0.25	-465.60	466.10	-0.77	-1.83	0.28	-141.55	-333.91	50.81	
Non-Concomitant Vaccines	BNT-162b2	232,484	1,272.4	0.29	-2.18	2.77	53.03	-399.18	505.24	-0.21	-1.81	1.38	-38.93	-330.27	252.40	
Seasonality Adjusted		289,115	1,582.0	-0.09	-2.38	2.19	-17.10	-434.33	400.12	-0.66	-1.95	0.63	-120.69	-356.99	115.61	
PPV-Adjusted		289,115	1,582.0	-0.18	-2.02	1.66	-32.25	-368.72	304.22	-0.49	-1.77	0.79	-89.93	-323.52	143.65	
Primary Analysis		192,540	1,053.6	3.22	-0.31	6.75	587.81	-57.35	1232.96	3.22	-0.31	6.75	587.81	-57.35	1232.96	
Farrington-Adjusted		192,540	1,053.6	2.49	0.19	4.80	455.55	33.94	877.15	2.49	0.19	4.80	455.55	33.94	877.15	
Non-Concomitant Vaccines	mRNA-1273	159,157	871.1	2.35	-0.66	5.36	429.54	-119.83	978.90	2.35	-0.66	5.36	429.54	-119.83	978.90	
Seasonality Adjusted	1	193,188	1,057.1	2.58	-0.21	5.38	472.23	-37.94	982.40	2.58	-0.21	5.38	472.23	-37.94	982.40	
PPV-Adjusted		193,188	1,057.1	2.33	-0.50	5.17	426.12	-92.18	944.43	2.33	-0.50	5.17	426.12	-92.18	944.43	

510 Table 3. Risk Difference (RD) Estimates for Primary and Sensitivity Meta-Analyses, Febrile Seizures (0-1 Days Outcome)

Meta-Analysis IRR Comparison, Primary Outcome: Febrile Seizure (0-1 Days)

Risk

Primary Analysis

Event Dependent Exposure Analysis

Non-Concomitant Vaccination Subgroup

Seasonality Adjusted Analysis

PPV Adjusted Analysis

Risk

medRxiv preprint doi: https://doi.org/10.1101/202403.7224304027; thi sign posice A gut 29, 224 The copyright holder for this preprint (which was not certified by peer review) is the autom/fender who has grantee allowed without permission

Event Dependent Exposure Analysis

Non-Concomitant Vaccination Subgroup

Seasonality Adjusted Analysis

PPV Adjusted Analysis

273

-

mRNA-

 Cases	Control Cases	
7	81	
7	81	
7	65	
7	81	
6	74	
 c Cases	Control Cases	
10	57	
10 10	57 57	
10 10 8	57 57 47	
10 10 10	57 57 47 57	
10 10 8 9	57 57 47 57 52	

